Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 1
2019 1
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer.
González-Vallinas M, Molina S, Vicente G, Zarza V, Martín-Hernández R, García-Risco MR, Fornari T, Reglero G, Ramírez de Molina A. González-Vallinas M, et al. PLoS One. 2014 Jun 3;9(6):e98556. doi: 10.1371/journal.pone.0098556. eCollection 2014. PLoS One. 2014. PMID: 24892299 Free PMC article.
In this work, five carnosic acid-rich supercritical rosemary extracts with different chemical compositions have been assayed for their antitumor activity both in vivo (in nude mice) and in vitro against colon and pancreatic cancer cells. ...Moreover, plasmati …
In this work, five carnosic acid-rich supercritical rosemary extracts with different chemical compositions have been assayed for thei …
Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells.
Lin JH, Chen SY, Lu CC, Lin JA, Yen GC. Lin JH, et al. Phytother Res. 2020 Aug;34(8):2053-2066. doi: 10.1002/ptr.6669. Epub 2020 Mar 17. Phytother Res. 2020. PMID: 32185829
Therefore, investigating the safety and the potential of new auxiliary methods for pancreatic cancer treatment is urgent. Ursolic acid (UA), a natural pentacyclic triterpenoid found in apple peels, rosemary, and thyme, has been reported to have anticancer cap …
Therefore, investigating the safety and the potential of new auxiliary methods for pancreatic cancer treatment is urgent. Urso …
Core outcome sets in cancer and their approaches to identifying and selecting patient-reported outcome measures: a systematic review.
Ramsey I, Eckert M, Hutchinson AD, Marker J, Corsini N. Ramsey I, et al. J Patient Rep Outcomes. 2020 Sep 15;4(1):77. doi: 10.1186/s41687-020-00244-3. J Patient Rep Outcomes. 2020. PMID: 32930891 Free PMC article. Review.
This review investigated the scope, outcomes, and development methods of consensus-based COS for cancer, and their approaches and criteria for selecting instruments to assess core patient-reported outcomes (PROs). ...RESULTS: Seventeen studies met the inclusion criteria. M …
This review investigated the scope, outcomes, and development methods of consensus-based COS for cancer, and their approaches and cri …
Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells.
Han S, Li X, Xia Y, Yu Z, Cai N, Malwal SR, Han X, Oldfield E, Zhang Y. Han S, et al. J Med Chem. 2019 Dec 12;62(23):10867-10896. doi: 10.1021/acs.jmedchem.9b01405. Epub 2019 Dec 2. J Med Chem. 2019. PMID: 31725297
HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently interest in the development of non-bisphosphonate inhibitors as cancer therapeutics. Here, we report the discovery and development of HsFPP …
HsFPPS is potently inhibited by bisphosphonates, but due to poor cell penetration and distribution in soft tissue, there is currently intere …
Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.
Starbuck K, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, Stein J, Dransfield DT, Zarrella B, Growdon WB, Behrens J, Foster R, Rueda BR. Starbuck K, et al. Oncotarget. 2018 May 1;9(33):23289-23305. doi: 10.18632/oncotarget.25289. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796189 Free PMC article.
Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. The Sialyl-Thomsen-nouveau antigen (STn) is a carbohydrate moiety pre …
Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells …